CRISPR Therapeutics AG Chief Medical Officer Naimish Patel filed a Form 4 on October 28, 2026, reporting the grant of a stock option for 24,000 common shares and a restricted stock unit award for 12,000 common shares, both dated October 26, 2026.

Key Highlights

  • Option grant: Naimish Patel received a stock option (right to buy) covering 24,000 common shares at an exercise price of $49.01, granted October 26, 2026, expiring October 26, 2036.
  • Vesting schedule (options): 100% of the 24,000 option shares vest in 48 equal monthly installments, with the first vesting date of November 26, 2026.
  • RSU grant: Patel also received a restricted stock unit award for 12,000 common shares, with each unit representing a contingent right to receive one CRSP common share.
  • RSU vesting schedule: The 12,000 RSUs vest in four equal annual installments on October 26 of each year from 2027 through 2030.
  • Price of derivative securities: Both the option and the RSU award were reported at a price of $0 at grant.
  • Direct ownership: Both the option and RSU positions are held directly by the reporting person.

Patel's October 2026 Equity Awards: Options and RSUs Detailed

According to the Form 4 filed with the SEC on October 28, 2026, Naimish Patel, Chief Medical Officer of CRISPR Therapeutics AG (NASDAQ:CRSP), acquired two derivative securities on October 26, 2026. The filing covers changes in beneficial ownership reported under Section 16(a) of the Securities Exchange Act of 1934 and was signed by Elizabeth Ryland Waldinger as attorney-in-fact.

The first award is a stock option granting Patel the right to buy 24,000 common shares at an exercise price of $49.01 per share. The filing states that "100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 26, 2026," and the option expires on October 26, 2036. Following the grant, Patel beneficially owns 24,000 shares underlying this option directly.

The second award is a restricted stock unit grant covering 12,000 common shares. The filing explains that each RSU "represents a contingent right to receive one share of CRSP Common Shares," and specifies that one quarter of the shares vests on each of October 26, 2027, October 26, 2028, October 26, 2029, and October 26, 2030. Patel holds all 12,000 RSUs directly. No shares were reported in Table I (non-derivative securities) in connection with these transactions.

What Was Disclosed

The filing reported two equity awards granted to CRISPR Therapeutics AG's Chief Medical Officer on October 26, 2026: a stock option for 24,000 common shares at $49.01 per share with a 48-month monthly vesting schedule, and a restricted stock unit award for 12,000 common shares vesting annually over four years.